Sangamo Therapeutics (SGMO) Research & Development (2016 - 2025)
Historic Research & Development for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $28.1 million.
- Sangamo Therapeutics' Research & Development rose 147.84% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.9 million, marking a year-over-year decrease of 2428.33%. This contributed to the annual value of $111.5 million for FY2024, which is 5235.31% down from last year.
- Latest data reveals that Sangamo Therapeutics reported Research & Development of $28.1 million as of Q3 2025, which was up 147.84% from $27.1 million recorded in Q2 2025.
- Sangamo Therapeutics' 5-year Research & Development high stood at $66.2 million for Q4 2022, and its period low was $23.7 million during Q4 2024.
- For the 5-year period, Sangamo Therapeutics' Research & Development averaged around $47.8 million, with its median value being $56.4 million (2021).
- Per our database at Business Quant, Sangamo Therapeutics' Research & Development soared by 4470.53% in 2021 and then tumbled by 6157.88% in 2024.
- Quarter analysis of 5 years shows Sangamo Therapeutics' Research & Development stood at $51.8 million in 2021, then increased by 27.76% to $66.2 million in 2022, then fell by 23.38% to $50.7 million in 2023, then crashed by 53.31% to $23.7 million in 2024, then increased by 18.87% to $28.1 million in 2025.
- Its last three reported values are $28.1 million in Q3 2025, $27.1 million for Q2 2025, and $26.0 million during Q1 2025.